FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017282092> ?p ?o ?g. }

• W2017282092 endingPage "349" @default.
• W2017282092 startingPage "349" @default.
• W2017282092 abstract "Patients with acute coronary syndrome (ACS) continue to be at risk for recurrent ischemic events, despite an early invasive strategy and the use of dual antiplatelet therapy. The anticoagulant pathway remains activated for a prolonged period after ACS and, consequently, has been a target for treatment. Early studies with warfarin indicated its benefit, but the risk of bleeding and the complexities of warfarin anticoagulation resulted in little use of this strategy. Rivaroxaban, apixaban, and dabigatran are new specific inhibitors of anticoagulant factors (Xa or IIa) currently available for the prevention of thrombosis and/or thromboembolism. Thus far, studies with dabigatran and apixaban in ACS have shown no clinical benefit and bleeding has been increased. The ATLAS ACS 2-TIMI 51 trial observed the impact of rivaroxaban 2.5 mg and 5 mg twice daily in patients with recent ACS receiving current management (both early invasive strategy and dual antiplatelet therapy with aspirin and clopidogrel) over a follow-up period of over 1 year. Rivaroxaban 2.5 mg twice daily reduced cardiovascular death, myocardial infarction, or stroke by 16%, and both cardiovascular and all-cause mortality by approximately 20%. Although major bleeding increased from 0.6% to 2.1% and intracranial hemorrhage from 0.2% to 0.6%, there was no increase in fatal bleeding. The role of rivaroxaban in the management of ACS is discussed in this review. The reduction in mortality is the main finding that could lead to the use of rivaroxaban in the management of ACS in high-risk individuals with a low bleeding risk." @default.
• W2017282092 created "2016-06-24" @default.
• W2017282092 creator A5048938163 @default.
• W2017282092 date "2012-11-01" @default.
• W2017282092 modified "2023-10-16" @default.
• W2017282092 title "Potential role of rivaroxaban in patients with acute coronary syndrome" @default.
• W2017282092 cites W1553345686 @default.
• W2017282092 cites W1564690174 @default.
• W2017282092 cites W1738640266 @default.
• W2017282092 cites W1973093958 @default.
• W2017282092 cites W1990538732 @default.
• W2017282092 cites W1991549653 @default.
• W2017282092 cites W2012328700 @default.
• W2017282092 cites W2032105970 @default.
• W2017282092 cites W2032335787 @default.
• W2017282092 cites W2040251457 @default.
• W2017282092 cites W2046051565 @default.
• W2017282092 cites W2092123807 @default.
• W2017282092 cites W2095901832 @default.
• W2017282092 cites W2097854437 @default.
• W2017282092 cites W2098837786 @default.
• W2017282092 cites W2108064339 @default.
• W2017282092 cites W2117677020 @default.
• W2017282092 cites W2119020141 @default.
• W2017282092 cites W2121251309 @default.
• W2017282092 cites W2121366426 @default.
• W2017282092 cites W2127090290 @default.
• W2017282092 cites W2131358454 @default.
• W2017282092 cites W2140501627 @default.
• W2017282092 cites W2144471064 @default.
• W2017282092 cites W2159370562 @default.
• W2017282092 cites W2167182965 @default.
• W2017282092 cites W2167918232 @default.
• W2017282092 cites W2169387542 @default.
• W2017282092 cites W2316460201 @default.
• W2017282092 cites W2327467387 @default.
• W2017282092 cites W2899026368 @default.
• W2017282092 cites W71090043 @default.
• W2017282092 cites W2004276659 @default.
• W2017282092 doi "https://doi.org/10.2147/dddt.s30342" @default.
• W2017282092 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3509996" @default.
• W2017282092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23209364" @default.
• W2017282092 hasPublicationYear "2012" @default.
• W2017282092 type Work @default.
• W2017282092 sameAs 2017282092 @default.
• W2017282092 citedByCount "3" @default.
• W2017282092 countsByYear W20172820922014 @default.
• W2017282092 countsByYear W20172820922022 @default.
• W2017282092 crossrefType "journal-article" @default.
• W2017282092 hasAuthorship W2017282092A5048938163 @default.
• W2017282092 hasBestOaLocation W20172820921 @default.
• W2017282092 hasConcept C126322002 @default.
• W2017282092 hasConcept C127413603 @default.
• W2017282092 hasConcept C164705383 @default.
• W2017282092 hasConcept C2776301958 @default.
• W2017282092 hasConcept C2777628954 @default.
• W2017282092 hasConcept C2777698277 @default.
• W2017282092 hasConcept C2777849778 @default.
• W2017282092 hasConcept C2778661090 @default.
• W2017282092 hasConcept C2778810321 @default.
• W2017282092 hasConcept C2779161974 @default.
• W2017282092 hasConcept C2780638905 @default.
• W2017282092 hasConcept C2780645631 @default.
• W2017282092 hasConcept C2780890252 @default.
• W2017282092 hasConcept C500558357 @default.
• W2017282092 hasConcept C71924100 @default.
• W2017282092 hasConcept C78519656 @default.
• W2017282092 hasConceptScore W2017282092C126322002 @default.
• W2017282092 hasConceptScore W2017282092C127413603 @default.
• W2017282092 hasConceptScore W2017282092C164705383 @default.
• W2017282092 hasConceptScore W2017282092C2776301958 @default.
• W2017282092 hasConceptScore W2017282092C2777628954 @default.
• W2017282092 hasConceptScore W2017282092C2777698277 @default.
• W2017282092 hasConceptScore W2017282092C2777849778 @default.
• W2017282092 hasConceptScore W2017282092C2778661090 @default.
• W2017282092 hasConceptScore W2017282092C2778810321 @default.
• W2017282092 hasConceptScore W2017282092C2779161974 @default.
• W2017282092 hasConceptScore W2017282092C2780638905 @default.
• W2017282092 hasConceptScore W2017282092C2780645631 @default.
• W2017282092 hasConceptScore W2017282092C2780890252 @default.
• W2017282092 hasConceptScore W2017282092C500558357 @default.
• W2017282092 hasConceptScore W2017282092C71924100 @default.
• W2017282092 hasConceptScore W2017282092C78519656 @default.
• W2017282092 hasLocation W20172820921 @default.
• W2017282092 hasLocation W20172820922 @default.
• W2017282092 hasLocation W20172820923 @default.
• W2017282092 hasLocation W20172820924 @default.
• W2017282092 hasOpenAccess W2017282092 @default.
• W2017282092 hasPrimaryLocation W20172820921 @default.
• W2017282092 hasRelatedWork W1993190469 @default.
• W2017282092 hasRelatedWork W2049310472 @default.
• W2017282092 hasRelatedWork W2321904733 @default.
• W2017282092 hasRelatedWork W2509901103 @default.
• W2017282092 hasRelatedWork W2789710191 @default.
• W2017282092 hasRelatedWork W2793392713 @default.
• W2017282092 hasRelatedWork W2918358868 @default.
• W2017282092 hasRelatedWork W2990629389 @default.
• W2017282092 hasRelatedWork W3016213733 @default.

• next